Market capitalization | $1.83b |
Enterprise Value | $1.49b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 5.67 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-250.64m |
Free Cash Flow (TTM) Free Cash Flow | $-184.08m |
Cash position | $342.52m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
8 Analysts have issued a Neumora Therapeutics forecast:
8 Analysts have issued a Neumora Therapeutics forecast:
Sep '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -0.64 -0.64 |
84%
84%
|
|
EBITDA | -250 -250 |
52%
52%
|
EBIT (Operating Income) EBIT | -251 -251 |
48%
48%
|
Net Profit | -294 -294 |
89%
89%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Neumora Therapeutics, Inc. is a clinical-stage biotechnology company. It offers a precision medicine approach for brain diseases through the integration of data science and neuroscience. The firm focuses on advancing medicines for therapeutically relevant targets implicated in CNS diseases, targeting novel mechanisms of action with best-in-class pharmacology. The company was founded by Paul L. Berns, Carol Suh and Mike Poole in November 2019 and is headquartered in Watertown, MA.
Head office | United States |
CEO | Henry Gosebruch |
Employees | 124 |
Founded | 2019 |
Website | www.neumoratx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.